NCT07519187

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Clinical Study on the Safety and Efficacy of CAR 70-BCMA Dual-Target CAR-T Therapy for Relapsed or Refractory Plasma Cell Neoplasms

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The General Hospital of Western Theater Command · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

Conditions

• Relapsed or Refractory Plasma Cell Neoplasms

Interventions

Type	Name	Description
GENETIC	CAR 70-BCMA CAR-T	Each subject will receive a single infusion of BCMA-CD70-CAR-T cells. A classic "3+3" dose escalation design will be employed.
DRUG	Fludarabine and Cyclophosphamide	Drug: Fludarabine Fludarabine will be administered intravenously (IV) at a dose of 30 mg/m²/day for 3 consecutive days prior to the infusion of 70-BCMA-CAR-T cells. Drug: Cyclophosphamide Cyclophosphamide will be administered intravenously (IV) at a dose of 300 mg/m²/day for 3 consecutive days prior to the infusion of 70-BCMA-CAR-T cells.

Timeline

• Start date: 2026-04-03
• Primary completion: 2027-04-01
• Completion: 2028-04-01
• First posted: 2026-04-09
• Last updated: 2026-04-09

Locations

1 site across 1 country: China